Skip to main
OCUL

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix is well-equipped for success with a highly specialized hydrogel platform technology and a diversified pipeline of highly promising therapies. With a strong leadership team and a high likelihood of approval for their novel eye medication, Dextenza, and the potential for future treatment options, including OTX-TIC, OTX-TKI, and OTX-IVT, there is significant potential for growth and success for Ocular Therapeutix. While there are risks involved, including competition from larger pharmaceutical companies and potential delays in clinical development and regulatory approvals, the company has a solid financial outlook with a current runway estimated to last through 2028 and a strong cash position of $667 million.

Bears say

Ocular Therapeutix is an integrated biopharmaceutical company focused on developing therapies for diseases and conditions of the eye. The company's success hinges on the potential approval of its investigational product candidate, AXPAXLI, for the treatment of wet age-related macular degeneration. However, there are several risks that could potentially hinder the approval and commercialization of AXPAXLI, including intellectual property challenges, clinical trial failures, and regulatory hurdles. In addition, the company's high operational expenses and dependency on the retinal disease treatment market pose significant financial and market risks.

Ocular Therapeutix (OCUL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Ocular Therapeutix (OCUL) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.